PepGen (PEPG)
(Delayed Data from NSDQ)
$9.01 USD
+0.31 (3.56%)
Updated Sep 11, 2024 04:00 PM ET
After-Market: $9.01 0.00 (0.00%) 7:46 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Price, Consensus and EPS Surprise
PEPG 9.01 +0.31(3.56%)
Will PEPG be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for PEPG based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for PEPG
Down -39.63% in 4 Weeks, Here's Why You Should You Buy the Dip in PepGen (PEPG)
Recent Price Trend in PepGen (PEPG) is Your Friend, Here's Why
PEPG: What are Zacks experts saying now?
Zacks Private Portfolio Services
Best Momentum Stocks to Buy for April 25th
New Strong Buy Stocks for April 25th
Can PepGen, Inc. (PEPG) Climb 48.62% to Reach the Level Wall Street Analysts Expect?
Other News for PEPG
Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q2 2024 Update
Dyne stock tumbles 31% amid drug updates, management changes
PepGen Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Executive Vice President, Research & Development
PepGen Appoints Paul Streck, M.D., MBA, as Executive Vice President, Head of Research & Development
Analysts Offer Insights on Healthcare Companies: Kura Oncology (KURA), Tenaya Therapeutics (TNYA) and PepGen Inc. (PEPG)